Cornell University

As part of the university's commitment to economic development and outreach, CTL hosts a variety of events to create connections between the Cornell campuses, industry members, entrepreneurs, and investors.

CTVF 2015

Sponsors

Breakfast


Bond, Shoeneck and King


Cayuga Venture Fund


LeClair Ryan


Lunch

Bond, Shoeneck and King


Scully Scott Murphy and Presser



CTVF 13

CTL will host its ninth annual Cornell Technology Venture Forum™ (CTVF) on Thursday, October 22, 2015 in the East Hill Office Building Training Room and Atrium (395 Pine Tree Road, Ithaca, NY). Emerging technologies and Cornell startups will be presented and showcased throughout the day. Ample networking and poster viewing breaks will allow attendees to mingle and form useful business relationships.


Poster and oral presentation topics will include: Agriculture and Plants, Diagnostics and Therapeutics, Materials Science, Medical Devices, Information Technology, and Nanotechnology. Inventors and CTL staff will be on hand to discuss potential partnerships and opportunities.


For more information, please contact Laura Salter at LC12@cornell.edu


Select Oral Presentations

  • Lionano, Inc.
    Lionano is a material manufacturing company commercializing advanced drop-in enhancements for lithium-ion batteries. Lionano’s materials have been shown to increase the energy density, rate capability, and cycle life of Li-ion batteries, especially in the application of electric vehicles.
  • TeraCam: Low Cost Portable Terahertz Imaging
    "TeraCam" is a low cost, harmless, and high precision camera based on terahertz (THz) electromagnetive radiation, which is non-ionizing and therefore harmless. The device is able to "see inside a black box." Promising applications are for the great majority of medical imaging systems and security applications. Additionallly, this device can be used to reveal the chemical composition of hidden objects.
  • Toward the Development of a Universal Vaccine Against Influenza
    A universal vaccine against influenza infection remains elusive. The highly mutagenic nature of the hemagglutinin and neuraminidase influenza antigens necessitates unique seasonal vaccine formulations to maintain a degree of protection for the population. Universal vaccines focus on conserved viral antigens (i.e., non-mutagenic), but they make poor vaccines. Our work focuses on the development of a universal vaccine against influenza in three ways. First, we focus on the conserved influenza protein, M2. Second, we generate delivery vehicles for the M2 protein that drive a directed and strong immune response against the protein. Third, we make these formulations using economically viable and scalable methods. In close collaboration with the Whittaker and DeLisa groups at Cornell, we have identified new universal influenza vaccine formulations that have conferred 100% protection against lethal doses in preclinical models of infection.
  • Xallient
    Xallient is developing the next generation of Scanning Probe Microscopes (SPM) for the advanced testing of semiconductor devices and thin-films at the micro- and nano-scales. Our patented technologies are based on integrating one or multiple tips with supporting sensing, actuation and electronics on a single probe chip. We design and fabricate these "probe platforms-on-a-chip" using advanced nanoelectromechanical system (NEMS) technologies, enabling simple and cost-effective miniaturization to the nanoscale. Our products enable engineers and researchers to analyze nanoscale devices and materials much more quickly and at a small fraction of the cost of conventional instruments.

Select Posters

  • AAV-mediated Persistent Bevacizumab Therapy Suppresses Tumor Growth of Ovarian Cancer
    Ovarian cancer is the most lethal gynecologic cancer and fifth leading cause of cancer in the United States. Ovarian cancer patient with high expression of the key angiogenesis factor, vascular endothelial growth factor (VEGF), is associated with poor progression-free survival and overall survival. One strategy to treat ovarian cancer is inhibition of angiogenesis.

    Bevacizumab is a humanized monoclonal IgG1 antibody that targets VEGF-A, a member of VEGF family involved in tumor angiogenesis. It has been approved by FDA to treat multiple cancers.

    This invention provides AAVrh.10BevMab, a rhesus sertotype 10 adeno-associated viral vector coding bevacizumab, for a single peritoneal administration of bevacizumab to treat ovarian cancer. The inventors demonstrated that: AAVrh.10BevMab mediates persistent and high levels of bevacizumab in the peritoneal cavity following a single intraperitoneal administration in mice. In AAVrh10.BevMab treated A2780 human ovarian cancer-bearing mice, tumor growth was significantly suppressed and the area of blood vessels in the tumor was decreased. An advantage to the method is it provides persistent and high levels of bevacizumab without repeated antibody administration.
  • 'Algonquin' Potato
    'Algonquin' is a white-skinned, early to mid-season tablestock variety. It features attractive large tubers that remain white after boiling and do not slough significantly. This variety displays nice vines, white flowers, and some fruit. 'Algonquin' has very good resistance to blackspot bruise, is resistant to race Ro1 of the golden nematode, and has good resistance to powdery scab.
  • Blocking TFGbeta Signaling as a Strategy to Reduce Chemotherapy-induced Myelosuppression
    Hematopoietic stem cells (HSCs) are required for lifelong blood cell production. Normally, the majority of HSCs are deeply quiescent but during times of hematologic stress—for example after chemotherapy, bone marrow transplantation, massive infection or bleeding—HSCs undergo extensive self-renewal and differentiation to meet increased hematopoietic demands.

    Weill Cornell researchers studied the mechanism for how these processes wind down after stress. This had never been studied previously. They found that transforming growth factor-β (TGFβ) signals drive activated HSCs back to homeostasis during recovery from the stress. Blockade of TGFβ after a hematopoietic stress delayed the return of HSCs to quiescence and accelerated hematopoietic reconstitution. The outcome was faster recovery of all blood cell counts after myelosuppressive chemotherapy and faster hematopoietic engraftment after transplantation. This could lead to a therapeutic target to stimulate recovery from myelosuppression or other causes of hematopoietic deficiency or stress.
  • Generation of Conditional Self-incompatible Inbred Lines and Self-fertile Hybrids
    A novel strategy of pollination control for the generation of hybrid cultivars and large-scale seed production from hybrid plants, particularly suited to brassicacea crops.
  • Ordered Gyroidal Mesoporous Carbon and Uses in Batteries and Other Energy Applications
    Cornell researchers have developed gyroidal mesoporous carbon matrix via a silica-free, metal- and halogen-free process that offers exceptional conductivity properties, stability, chemical inertness and low density. Due to organic-organic assembly, the pore sizes are large, narrowly dispersed and reproducible. Both double and single gyroidal carbon networks have been synthesized. Potential applications include electrodes in fuel cells, batteries, and supercapacitors.
  • Sequence-defined Polymers using Allyl Acrylamide Building Blocks
    Synthetic efforts towards controlling polymer sequence in a pre-defined order along a polymer chain, has proven to be a difficult challenge. This invention uses orthogonal allyl acrylamide building blocks for the design and synthesis of sequence-specific polymers; some of which could not be synthesized using other methods.
  • UMA Bioseed (Subsidiary of ZYMtronix)
    UMA Bioseed is developing and commercializing a patent-pending, enzyme-based solution for seed treatment. Uma's product protects agricultural seeds by eliminating and controlling plant pathogens (bacteria and fungi) both on and around the seed throughout the  critical germination phase for higher crop yields, lower chemical use and greater food security.
  • 'Upstate Abundance' Potato
    'Upstate Abundance' - synonym 'Baby Blanca' in Canada - is a bright white-skinned, early-season tablestock variety. It features very small round tubers that remain white after boiling and do not slough significantly. 'Upstate Abundance' is resistant to race Ro1 of the golden nematode, and shows intermediate resistance to common scab.
  • ZYMtronix Catalytic Systems, Inc.
    Phenol and its derivatives are produced in a wide variety of industrial processes and make up the majority of EPA-regulated compounds under the Clean Water Act. Traditional methods of removing phenol from wastewater are costly, use a lot of materials, and often do not convert the compounds into less reactive forms. This company's solution traps enzymes in metal oxide nanoparticle cages and places them on scaffolds, which is ten times more efficient and reusable.